Tempest Therapeutics Reports 100% Complete Response Rate for TPST-2003 in Multiple Myeloma, Plans U.S. Registrational Study

summarizeSummary

Tempest Therapeutics announced highly positive interim clinical data for its TPST-2003 CAR-T therapy in relapsed/refractory multiple myeloma, showing a 100% complete response rate in evaluable patients and a favorable safety profile, leading to plans for a U.S. registrational study in 2026.

check_boxKey Events

• Interim Clinical Data for TPST-2003

  Reported a 100% complete response (CR) rate among all six efficacy-evaluable patients in the ongoing REDEEM-1 trial for relapsed/refractory multiple myeloma.

• Favorable Safety Profile

  Observed a favorable safety profile with no Grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) in the REDEEM-1 trial.

• Durable Responses Demonstrated

  A prior investigator-initiated trial (IIT) of TPST-2003 reached a median progression-free survival (PFS) of 23.1 months, including in patients with extramedullary disease.

• U.S. Registrational Study Planned

  Tempest plans to submit a U.S. IND application and, subject to clearance, initiate a U.S. registrational study for TPST-2003 in 2026.

auto_awesomeAnalysis

This 8-K reports significant positive interim clinical data for Tempest Therapeutics' TPST-2003 program, a CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. The 100% complete response rate observed in all six efficacy-evaluable patients in the REDEEM-1 trial, coupled with a favorable safety profile and durable responses from a prior investigator-initiated trial, represents a major de-risking event for this clinical-stage asset. The company's decision to accelerate development and prepare for a U.S. registrational study in 2026 indicates strong confidence in the therapy's potential. For a micro-cap biotechnology company, such compelling clinical results and a clear path to a pivotal study are highly market-moving, potentially attracting significant investor interest and validating its cell therapy platform.